beta
Trial Radar AI
Clinical Trial NCT06813742 for Pheochromocytoma is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

18F-mFBG PET Imaging in the Evaluation of Pheochromocytoma 80

Recruiting
Clinical Trial NCT06813742 is an observational study for Pheochromocytoma that is recruiting. It started on 1 May 2023 with plans to enroll 80 participants. Led by First Affiliated Hospital of Zhejiang University, it is expected to complete by 1 December 2026. The latest data from ClinicalTrials.gov was last updated on 7 August 2025.
Brief Summary
The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with pheochromocytoma.
Detailed Description
Pheochromocytoma highly expresses norepinephrine transporter (NET) which is targeted by function alanalogue of norepinephrine, 123/131I-MlBG. However, low spatial resolution of 123/131I-MlBG and inaccurate attenuation correction of single photon emission tomography (SPECT/CT) will affect the image quality of MlBG SPECT and lead to poor diagnosis of small lesions. In addition, 123l-MlBG imaging is usually performed at...Show More
Official Title

A Prospective Exploratory Study Evaluating the Diagnostic Usefulness of 18F-mFBG PET Imaging in Pheochromocytoma

Conditions
Pheochromocytoma
Other Study IDs
  • FAHZU-MFBG-PHEO
NCT ID Number
NCT06813742
Start Date (Actual)
2023-05-01
Last Update Posted
2025-08-07
Completion Date (Estimated)
2026-12
Enrollment (Estimated)
80
Study Type
Observational
Status
Recruiting
Arms / Interventions
Participant Group/ArmIntervention/Treatment
18F-MFBG PET/CT in Pheochromocytoma
Each patient receive a single intravenous injection of 18F-MFBG 5.55 MBq/kg and undergo PET/CT or PET/MR scan after 60 min post-injection.
18F-MFBG
Patients with pheochromocytoma malignancies receive 5.55 MBq/kg of 18F-MFBG intravenously followed by PET/CT or PET/MR after 60min of injection.
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Correlation between positive and negative 18F-mFBG PET/CT or PET/MR Imaging and pathological diagnosis and treatment effect in patients with pheochromocytoma.
Main outcome measure
through study completion, an average of 1 year
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
False positive and false negative results of 18F-mFBG PET/CT or PET/MR Imaging in patients with pheochromocytoma.
Secondary outcome measure
through study completion, an average of 1 year
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  1. Aged 30-80 years old, primary school or above, with a regular caregiver;
  2. Clinically diagnosed patients with pheochromocytoma;
  3. Can provide informed consent, can understand and comply with the study requirements.

  1. Patients with serious primary diseases such as heart, brain, liver, kidney and hematopoietic system;
  2. Uncontrolled hypertension or high-risk BP (i.e., systolic BP > 180 mmHg or diastolic BP > 110 mmHg);
  3. Patients with mental disorders or primary affective disorders;
  4. Unable to understand and adhere to the study protocol or provide informed consent;
  5. Contraindications to PET imaging (including pregnant women, lactating women, and women of childbearing age with recent childbearing plans, etc.);
  6. Allergy to imaging agents;
  7. Patients who were unable to cooperate with PET scanning, such as hypoglycemia, severe pain or tremor.
First Affiliated Hospital of Zhejiang University logoFirst Affiliated Hospital of Zhejiang University
Study Central Contact
Contact: Peipei Wang, MD, 86 18511395988, [email protected]
2 Study Locations in 1 Countries

Zhejiang

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310003, China
Xinhui Su, MD, Contact, 86 13806071262, [email protected]
Recruiting
The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310006, China
Peipei Wang, MD, Contact, 86 18511395988, [email protected]
Xinhui Su, MD, Contact, 86 13806071262, [email protected]
Recruiting